Cargando…

Apligraf as an Alternative to Skin Grafting in the Pediatric Population

Split-thickness skin grafting and healing by secondary intention are the most common options for the treatment of full-thickness skin injuries. This case explores Apligraf (Organogenesis Inc., Canton, Massachusetts) as an alternative treatment for full-thickness skin injuries in the pediatric popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Eudy, Morgan, Eudy, Christi L, Roy, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343621/
https://www.ncbi.nlm.nih.gov/pubmed/34367826
http://dx.doi.org/10.7759/cureus.16226
_version_ 1783734325293875200
author Eudy, Morgan
Eudy, Christi L
Roy, Samuel
author_facet Eudy, Morgan
Eudy, Christi L
Roy, Samuel
author_sort Eudy, Morgan
collection PubMed
description Split-thickness skin grafting and healing by secondary intention are the most common options for the treatment of full-thickness skin injuries. This case explores Apligraf (Organogenesis Inc., Canton, Massachusetts) as an alternative treatment for full-thickness skin injuries in the pediatric population. Apligraf, a bioengineered living cell construct, is an advanced wound care modality that is commonly used to treat chronic, nonhealing venous leg ulcers and diabetic foot ulcers. This case demonstrates Apligraf as a viable, if not superior, treatment option for full-thickness skin injury.
format Online
Article
Text
id pubmed-8343621
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-83436212021-08-07 Apligraf as an Alternative to Skin Grafting in the Pediatric Population Eudy, Morgan Eudy, Christi L Roy, Samuel Cureus Pediatrics Split-thickness skin grafting and healing by secondary intention are the most common options for the treatment of full-thickness skin injuries. This case explores Apligraf (Organogenesis Inc., Canton, Massachusetts) as an alternative treatment for full-thickness skin injuries in the pediatric population. Apligraf, a bioengineered living cell construct, is an advanced wound care modality that is commonly used to treat chronic, nonhealing venous leg ulcers and diabetic foot ulcers. This case demonstrates Apligraf as a viable, if not superior, treatment option for full-thickness skin injury. Cureus 2021-07-07 /pmc/articles/PMC8343621/ /pubmed/34367826 http://dx.doi.org/10.7759/cureus.16226 Text en Copyright © 2021, Eudy et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pediatrics
Eudy, Morgan
Eudy, Christi L
Roy, Samuel
Apligraf as an Alternative to Skin Grafting in the Pediatric Population
title Apligraf as an Alternative to Skin Grafting in the Pediatric Population
title_full Apligraf as an Alternative to Skin Grafting in the Pediatric Population
title_fullStr Apligraf as an Alternative to Skin Grafting in the Pediatric Population
title_full_unstemmed Apligraf as an Alternative to Skin Grafting in the Pediatric Population
title_short Apligraf as an Alternative to Skin Grafting in the Pediatric Population
title_sort apligraf as an alternative to skin grafting in the pediatric population
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343621/
https://www.ncbi.nlm.nih.gov/pubmed/34367826
http://dx.doi.org/10.7759/cureus.16226
work_keys_str_mv AT eudymorgan apligrafasanalternativetoskingraftinginthepediatricpopulation
AT eudychristil apligrafasanalternativetoskingraftinginthepediatricpopulation
AT roysamuel apligrafasanalternativetoskingraftinginthepediatricpopulation